Navio MD Review
Semaglutide & tirzepatide GLP-1 weight-loss telehealth · Independently scored 8.3/10
Best for: moving between compounded and brand without changing seller
Navio MD's strongest column is the clinical side — which molecules it will prescribe, and how it handles dosing.
Covered by the monthly price
Medication
Not stated
Clinician visits
Not stated
Shipping
Not stated
Lab work
Not stated
Coaching
Not stated
No insurance needed · Vetted by our editors
NavioMD sells compounded tirzepatide at $247/mo plus brand-name Ozempic at $1,199/mo and Mounjaro at $1,249/mo. It is LegitScript verified and available in 48 states, not AL or MS. The price is the same at every dose. It also offers women's hormone optimization.
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
Vetted alternatives to Navio MD
Editorial score · methodology
Editorial score · methodology
Editorial score · methodology
Navio MD at a glance
- Type
- GLP-1 telehealth provider
- Medications
- Tirzepatide, Ozempic, Zepbound, Mounjaro
- Starting price
- $189/mo (as low as $189/mo; tiered by dose)
- Pricing model
- Scales with dose — higher doses cost more
- Availability
- 48 states
- FDA status
- No FDA warning letter on record
How Navio MD scores
Six columns, each one computed from something Navio MD has published rather than from an opinion we formed: what it charges, which molecules it will dispense, what its record shows, and what the monthly figure actually buys. Where it publishes nothing, that absence is what gets scored. Every seller in the register goes through the same six columns.
Value25%
7.5/10$189/month is 29% below the register median of $267 for compounded tirzepatide.
Effectiveness25%
10.0/10Dispenses semaglutide and tirzepatide, including the FDA-approved product. Anchored to SURMOUNT-1 (tirzepatide, -20.9%) and STEP 1 (semaglutide, -14.9%).
User Experience15%
8.0/10On the seller's own pages, a price is published before the questionnaire starts.
Trust & Safety15%
8.5/10does not name a dispensing pharmacy; shows a price before asking for health information; publishes its state list. Our verification confidence is high.
Accessibility10%
9.7/10Publishes coverage in 48 of 50 states.
Support10%
5.0/10States too little about what the monthly cost covers to score the bundle. Held at the midpoint rather than assumed.
A seller that will not show a price before an intake loses points on Value and carries that note in its review. Withholding the number is itself a finding. How we score →
What we checked on Navio MD
Last checked August 2026- Re-read the price on file across 5 dose or plan tiers
- Checked state coverage: all 50
- Searched our FDA enforcement register for this operator
Price, availability, and compliance here are read off the seller's own pages and off primary regulatory records, named in the sources below. Editorial confidence in this data: high.
What signing up with Navio MD involves
Assembled from this seller’s entry in the register — the price record, the state list, the dispensing pharmacy where one is named, and what the monthly figure covers. It describes what a reader can expect to meet on the way to a prescription, and what is missing from the seller’s own disclosures. It is not a clinical judgment and not a prescribing decision.
- 1Navio MD publishes a price on its own site before asking anything about you. You can compare it against this register without starting a questionnaire.
- 2The intake is a written questionnaire. No live video visit or baseline bloodwork is recorded as required.
- 3Navio MD does not say which pharmacy dispenses the medication. That is common here and it means you cannot check the pharmacy's record before you buy.
- Cheapest standing monthly prices on record: tirzepatide $189, a GLP-1 $345. Membership fees, first-month rates and insured copays are excluded from those figures.
- Coverage is published for 48 of 50 states.
- The medication is compounded, so it is not an FDA-approved product and has not been reviewed by the agency for safety, effectiveness or manufacturing quality.
Navio MD support, as documented
- Phone
- 1 (877) 276-2846
- support@naviomd.com
- Hours
- 9am-10pm EST, Mon-Sun
GLP-1 medications Navio MD offers
Each one has its own guide: how the molecule works, the dosing schedule, the side effects that show up in practice, and what the trials actually measured.
Pricing
Prices re-verified
as low as $189/mo; tiered by dose
as low as $345/mo; brand price varies by dose
as low as $445/mo; tiered by dose
as low as $1,249/mo; tiered by dose
Ozempic as low as $345/mo (compounded tirzepatide $189/mo also offered)
Check the price yourself before you pay
Every figure here was read off Navio MD's own checkout on the date shown. Sellers move prices without announcing it, and promotional rates lapse, so confirm the standing cost on their site before committing.
In its favor
- Semaglutide at $345 a month, 73% below the $1299 median for the same drug and form across this register
- Publishes a price on its own site before the medical questionnaire, so it can be compared without handing over health information
- Coverage is published for 48 states
- No FDA warning letter matched this operator when we searched our enforcement register
Against it
- No dispensing pharmacy is named in our record, so its accreditation cannot be looked up from here
- Its tirzepatide is compounded rather than FDA-approved, so it has not been reviewed by the agency for safety, effectiveness or manufacturing quality
What Navio MD charges
The standing price at Navio MD is $189/month.
- Compounded tirzepatide — $189/month
- Brand-name Ozempic — $345/month
- Brand-name Zepbound — $445/month
- Brand-name Mounjaro — $1249/month
- Brand-name semaglutide — $345/month
The median across the GLP-1 providers we track is about $169/month, so this lands mid-market — close enough that the deciding factor is unlikely to be price.
Found dispenses semaglutide and tirzepatide from $149/month, which makes it the honest comparison to run before committing here.
What Navio MD dispenses
Navio MD prescribes semaglutide (approved as Wegovy and Ozempic) and tirzepatide (approved as Zepbound and Mounjaro). Between them these are the two molecules with the largest published weight-loss trial programs behind them. You can take the approved brand pen or the cheaper compounded preparation. What separates them is review: the approved product went through it, the compounded one did not, and that is the whole of the trade.
What we could verify
On the record: it treats patients in all 50 states. We searched the federal warning-letter record for this operator and came back with nothing. Because the medication is compounded and no dispensing pharmacy is named publicly, the single most useful question to ask at intake is which licensed pharmacy fills the prescription. A seller that will not answer that has told you something. How we weigh oversight, disclosure and price evidence is set out in our scoring methodology.
Who should look elsewhere
- You need to bill insurance. Like most of this market, this is cash-pay.
It fits if
- you need access regardless of where you live
Our read
Navio MD lands mid-market on price without a standout advantage or an obvious problem. It comes down to whether its particular package fits. Breeze Meds is the nearest comparison we track, and worth reading alongside this.
The Bottom Line
Navio MD's strongest column is the clinical side — which molecules it will prescribe, and how it handles dosing.
Before you pay Navio MD
Starting at $189/month. Check today's price, then book the free consultation.
Where Navio MD is the wrong choice
No seller in this register suits every reader, and saying otherwise would be the easiest way to sell one. On these four counts another entry does better.
Frequently Asked Questions
Glossary
The words sellers use, defined. Tap any term.
- Semaglutide · Drugs and brands
- Tirzepatide · Drugs and brands
- Compounded GLP-1 · Pharmacy and drug forms
- 503A pharmacy · Pharmacy and drug forms
- PCAB accreditation · Pharmacy and drug forms
- Prior authorization (PA) · Insurance and regulatory
- Off-label use · Insurance and regulatory
- FDA Drug Shortage List · Insurance and regulatory
Sources
Cited across this Navio MD review: primary regulatory filings, and peer-reviewed studies.
Sources & methodology — as of August 2026
- 1.GLP Watchdog — GLP-1 Pricing Index 2026 (our independent dataset)— GLP Watchdog.
- 2.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
- 3.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
- 4.PCAB — Pharmacy Compounding Accreditation Board Standards— Accreditation Commission for Health Care (ACHC) / PCAB.
- 5.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)— Kaiser Family Foundation.
- 6.STEP 1 Trial — Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding JPH et al.)— New England Journal of Medicine.PMID: 33567185.
- 7.FDA — Wegovy (semaglutide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 8.FDA — Ozempic (semaglutide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 9.SURMOUNT-1 Trial — Tirzepatide Once Weekly for the Treatment of Obesity (Jastreboff AM et al.)— New England Journal of Medicine.PMID: 35658024.
- 10.FDA — Zepbound (tirzepatide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 11.FDA — Mounjaro (tirzepatide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 12.SURMOUNT-5 Trial — Tirzepatide vs. Semaglutide Head-to-Head in Obesity (Garvey WT et al.)— New England Journal of Medicine.PMID: 40334173.
See Navio MD's current pricing
Plans start at $189/month. The free consultation is where you learn whether you qualify, and what it costs today.